Medgend Icon


Bydureon FDA Approved Drugs

BYDUREON [Exenatide Synthetic]
RX
-
2mg/vial (subcutaneous for suspension, extended release)
Astrazeneca AbJan 27, 2012
  • As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
  • Lowering plasma glucagon in a subject in need thereof, including one with type 2 diabetes, by administering an exendin or analog, such as exendin-4.
  • Method for treating type 2 diabetes using a sustained-release composition containing exenatide.
  • Reducing food intake in a subject with type 2 diabetes by administering an exendin, such as exendin-4.
  • Reducing gastric motility or delaying gastric emptying by administering an exendin, such as exendin-4.
  • Reductions in body weight are observed with exenatide.
  • Treating type 2 diabetes mellitus with exenatide by stimulating insulin release.
  • Treatment of type 2 diabetes.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

BYDUREON PEN [Exenatide Synthetic]
RX
-
2mg (subcutaneous for suspension, extended release)
Astrazeneca AbFeb 28, 2014
  • As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
  • Lowering plasma glucagon in a subject in need thereof, including one with type 2 diabetes, by administering an exendin or analog, such as exendin-4.
  • Method for treating type 2 diabetes using a sustained-release composition containing exenatide.
  • Reducing food intake in a subject with type 2 diabetes by administering an exendin, such as exendin-4.
  • Reducing gastric motility or delaying gastric emptying by administering an exendin, such as exendin-4.
  • Reductions in body weight are observed with exenatide.
  • Treating type 2 diabetes mellitus with exenatide by stimulating insulin release.
  • Treatment of type 2 diabetes.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

BYETTA [Exenatide Synthetic]
RX
-
300mcg/1.2ml (250mcg/ml) (subcutaneous injectable)
600mcg/2.4ml (250mcg/ml) (subcutaneous injectable)
Astrazeneca AbApr 28, 2005
  • Lowering plasma glucagon in a subject in need thereof, including one with type 2 diabetes, by administering an exendin or analog, such as exendin-4.
  • Reducing food intake in a subject with type 2 diabetes by administering an exendin, such as exendin-4.
  • Reducing gastric motility or delaying gastric emptying by administering an exendin, such as exendin-4.
  • Stimulating insulin release by administering exenatide.
  • Treating type 2 diabetes mellitus with exenatide by stimulating insulin release.
  • Use of exenatide may result in reduction in appetite..
  • Use of exenatide may result in reduction in body weight.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

WARNING: Consult a licensed physician in the appropriate field for medical treatment and drug prescription. Do not self medicate.